Ikaika Therapeutics

Ikaika Therapeutics is developing antibodies targeting fibrotic diseases, including muscular dystrophy. Its IKN-001 antibody binds to LTBP4, and the company says TGF-β then remains sequestered in an inactive state, which prevents fibrosis accumulation. Its pipeline page lists Duchenne muscular dystrophy and limb-girdle muscular dystrophy. Source

Keywords: antibodies fibrotic diseases muscular dystrophy LTBP4 IKN-001 TGF-β Duchenne muscular dystrophy limb-girdle muscular dystrophy Show all 8 keywords